Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.55 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9954345 | 0.86 | BRD4 (0.44) | PTGS2PTGS1GPBAR1KMT2ABRD4 | |
| SCHEMBL195456 | 0.83 | PTGS2 (0.58) | PTGS2PTGS1KMT2ABRD4LMNA | |
| SCHEMBL21752799 | 0.81 | GPBAR1 (0.48) | PTGS2PTGS1GPBAR1BRD4GABRA5 | |
| SCHEMBL6096442 | 0.81 | MAPK1 (0.43) | PTGS2PTGS1KMT2ABRD4LMNA | |
| SCHEMBL285616 | 0.78 | GABRA5 (0.46) | PTGS2PTGS1GPBAR1ATMGABRA5 | |
| SCHEMBL8264062 | 0.77 | PTGS2 (0.54) | PTGS2PTGS1GPBAR1KMT2AATM | |
| SCHEMBL4790252 | 0.76 | GABRA5 (0.49) | PTGS2GABRA5 | |
| SCHEMBL25624237 | 0.76 | PTGS2 (0.39) | PTGS2PTGS1GPBAR1GABRA5 | |
| SCHEMBL9956465 | 0.74 | GPBAR1 (0.46) | PTGS2PTGS1GPBAR1KMT2ABRD4 | |
| SCHEMBL27936743 | 0.74 | PTGS1 (0.50) | PTGS2PTGS1GPBAR1KMT2AGABRA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103201268-A | Novel piperazine analogs as broad-spectrum influenza antivirals | BRISTOL MYERS SQUIBB CO | 2013-07-10 | — | — | CN | disclosed |
| US-8163728-B2 | Pyrazoles | HOFFMANN-LA ROCHE INC. (US) | 2012-04-24 | — | — | US | disclosed |
| CN-102414205-A | Isoxazole-pyrazole derivatives | HOFFMANN LA ROCHE | 2012-04-11 | — | — | CN | disclosed |
| EP-2427455-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127975-A1 | ISOXAZOLE-PYRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| US-20100286115-A1 | PYRAZOLES | ROCHE PALO ALTO LLC | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286115-A1 | PYRAZOLES | GABRA5, GABRA1, GABRA3 | PTGS2 1849/4885PTGS1 1171/4885GPBAR1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.